We are proud to announce another research paper from the
Predict-PD stable. We have published our data from the imaging substudy of the
first phase of our research.
50 individuals who had gone through the website had a scan
showing dopamine-releasing areas in the brain (known as a DAT-SPECT or DATSCAN)
and transcranial ultrasound. The DATSCAN is the closest we have to a scan that
gives proof of Parkinson’s in the brain.
Ultrasound shows an area in the region most affected by Parkinson’s that is
brighter in people with Parkinson’s compared to healthy people.
Our findings show that the reductions in the dopamine scan
were correlated with risk scores, worse movement scores both on clinical
assessment and using the keyboard tapping test, and worse sense of smell. The
ultrasound scan also correlated with risk score and motor score on clinical
assessment.
These findings show that the risk score calculated from the
responses on the website are associated with changes on brain scans that are associated
with established Parkinson’s. This is exciting news, not just for us, but it
has established that there are hard changes in the brains of those at the
highest risk that are very likely to be the earliest signs of Parkinson’s.
These scans may well be used to prove eligibility for people to be
included in future drug trials to slow,
stop or prevent the diagnosis.
What are the next steps? I’ll be repeating this on a larger
sample, and not just using DATSCAN and ultrasound but MRI too, which will give
a highly detailed map of the strucutre of the brain. I look forward to sharing
these results with you in the next few years.
RNR
Dopamine reuptake transporter–single-photon emission
computed tomography and transcranial sonography as imaging markers of
prediagnostic Parkinson's disease
Authors
Alastair J. Noyce MRCP, PhD, John
Dickson PhD, Richard N. Rees MRCP, Jonathan P. Bestwick MSc, Ioannis U. Isaias
MD, PhD, Marios Politis MD, PhD, Gavin Giovannoni FRCP, PhD, Thomas T. Warner
FRCP, PhD, Andrew J. Lees FRCP, MD, Anette Schrag FRCP, PhD
- First
published: 30 January 2018
ABSTRACT
Objective: The objective of this study was to examine
whether prediagnostic features of Parkinson's disease (PD) were associated with
changes in dopamine reuptake transporter–single-photon emission computed
tomography and transcranial sonography.
Methods: Prediagnostic features of PD (risk
estimates, University of Pennsylvania Smell Identification Test, Rapid Eye
Movement Sleep Behavior Disorder Screening Questionnaire, and finger-tapping
scores) were assessed in a large cohort of older U.K. residents. A total of 46
participants were included in analyses of prediagnostic features and MDS-UPDRS
scores with the striatal binding ratio on dopamine reuptake
transporter–single-photon emission computed tomography and nigral hyperechogenicity
on transcranial sonography.
Results: The striatal binding ratio was associated
with PD risk estimates (P = .040), University of Pennsylvania Smell
Identification Test (P = .002), Rapid Eye Movement Sleep Behavior
Disorder Screening Questionnaire scores (P = .024), tapping speed (P = .024),
and MDS-UPDRS motor scores (P = .009). Remotely collected assessments
explained 26% of variation in the striatal binding ratio. The inclusion of
MDS-UPDRS motor scores did not explain additional variance. The size of the
nigral echogenic area on transcranial sonography was associated with risk
estimates (P < .001) and MDS-UPDRS scores (P = .03) only.
Conclusions: The dopamine reuptake
transporter–single-photon emission computed tomography results correlated with motor
and nonmotor features of prediagnostic PD, supporting its potential use as a
marker in the prodromal phase of PD. Transcranial sonography results also
correlated with risk scores and motor signs.